LLS Children’s Initiative and PedAL Trial
Returning guest, Dr. Gwen Nichols, Chief Medical Officer at the Leukemia & Lymphoma Society (LLS) discusses the Children’s Initiative, a $100M dollar effort to address the lack of treatments for pediatric blood cancers. She also talks about the PedAL trial that is part of the Children’s Initiative. This master clinical trial will test simultaneously multiple targeted therapies for children who experience a relapse of their acute leukemia. The study will take place at more than 200 sites worldwide that are part of the NCI-supported Children’s Oncology Group (COG) network of children’s hospitals, including those in the U.S., Australia, New Zealand, and Canada.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Gwen Nichols, Chief Medical Officer at the Leukemia & Lymphoma Society (LLS) discusses the Children’s Initiative, a $100M dollar effort to address the lack of treatments for…
- Key Point: This master clinical trial will test simultaneously multiple targeted therapies for children who experience a relapse of their acute leukemia.
- Key Point: The study will take place at more than 200 sites worldwide that are part of the NCI-supported Children’s Oncology Group (COG) network of children’s hospitals, including tho…
- Key Point: She oversees LLS’s scientific research portfolio, patient services and policy, and advocacy initiatives.
- Key Point: A physician and scientific researcher, she has dedicated her career to advancing cures for cancers.
As LLS’s chief medical officer (CMO), Gwen Nichols, M.D., plays a critical role in advancing cures through a unique combination of clinical, academic, and pharmaceutical experience. She oversees LLS’s scientific research portfolio, patient services and policy, and advocacy initiatives. A physician and scientific researcher, she has dedicated her career to advancing cures for cancers.
Most recently, Dr. Nichols was oncology site head of the Roche Translational Clinical Research Center, where she worked to develop new cancer therapies, translating them from the laboratory to clinical trials. Prior to joining Roche in 2007, Dr. Nichols was at Columbia University for more than ten years, where she served as the director of the Hematologic Malignancies Program.
While at Columbia University, Dr. Nichols maintained an active clinical practice and received the prestigious honors of “Physician of the Year” from Columbia University and the “Humanism in Medicine Award” from the American Association of Medical Colleges.
Dr. Nichols trained in internal medicine at the University of Chicago and completed post-doctoral research and a hematology-oncology fellowship at Memorial Sloan-Kettering Cancer Center where she was an attending physician. She received her medical degree with honors from the State University of New York at Buffalo.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


